SCHEDULE: FMR LLC & Abigail Johnson Boost Zenas BioPharma Stake to 11%

FMR LLC and Abigail P. Johnson have reported an 11.0% beneficial ownership stake in Zenas BioPharma Inc.'s common stock as of August 29, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 4,644,279 shares of Zenas BioPharma Inc. common stock.
• This represents an 11.0% stake in the company's common stock.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• FMR LLC, a Delaware-organized entity, holds sole voting power over 4,643,356 shares and sole dispositive power over 4,644,279 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 4,644,279 shares, reflecting her indirect control through FMR LLC.
• Key subsidiaries involved include FIAM LLC (Investment Adviser), Fidelity Institutional Asset Management Trust Company (Bank), and Fidelity Management & Research Company LLC (Investment Adviser), with the latter beneficially owning 5% or more.
• The Johnson family, including Abigail P. Johnson, forms a controlling group with respect to FMR LLC through their ownership of Series B voting common shares and a shareholders' voting agreement.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment by a reputable firm, which is generally a positive signal for investor confidence. No negative information about the issuer is present.

Positives

• Significant institutional investment from FMR LLC, a major financial services firm, indicates confidence in Zenas BioPharma Inc.
• The investment is stated to be for ordinary course of business, suggesting a passive, long-term holding rather than an activist stance.

Future Outlook

No forward-looking statements or guidance for Zenas BioPharma Inc. are provided in this ownership disclosure.

Industry Context

This filing indicates continued or increased institutional interest in the biopharma sector, specifically Zenas BioPharma Inc., from a major asset manager like FMR LLC.

Comparison to Industry Standards

• FMR LLC is a prominent institutional investor, and its 11.0% stake in Zenas BioPharma Inc. is a substantial passive investment, typical for large asset managers taking significant positions in public companies.
• Such ownership levels are common for funds managed by entities like Fidelity (FMR LLC's primary operating company) across various sectors, including biotechnology and pharmaceuticals.
• For example, other biopharma companies often see similar institutional ownership percentages from large mutual fund families or asset managers, indicating a standard practice for portfolio diversification and long-term holding.

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional backing from a major asset manager.
• Potential Investors: May view the company more favorably due to the reported institutional interest, potentially attracting further investment.

Key Dates

Recommendation

The filing indicates a significant 11.0% beneficial ownership stake by FMR LLC and Abigail P. Johnson in Zenas BioPharma Inc. This substantial institutional investment from a reputable firm is generally a positive signal, suggesting confidence in the company. However, a Schedule 13G is purely an ownership disclosure and does not provide new operational or financial performance data for Zenas BioPharma Inc. While the institutional backing is a supportive factor, it does not, on its own, provide sufficient new information to warrant an immediate 'buy' or 'sell' recommendation. For existing investors, it reinforces a 'hold' position, and for potential investors, it signals a company with notable institutional interest, prompting further fundamental analysis of Zenas BioPharma's business and financials.

Keywords

Zenas BioPharma Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biopharma, Fidelity